Lowering transplant rejection risk in young children
Part of Blood & lymphatic, Genetic & congenital, Immune system & allergy clinical trials.
This trial tests a way to lower the risk of graft-versus-host disease (GVHD), a common complication after a bone marrow transplant, by removing certain immune cells from the donor's stem cells before giving them to the patient. It is for young children with non-cancerous blood or immune diseases who need a transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Patient is between 6 months and 5 years old (inclusive) at the time of agreeing to take part.
- Patient has a non-cancerous blood or immune system disease that can be treated with a bone marrow transplant, such as certain anemias, sickle cell disease, immune deficiencies, or immune regulation problems.
- A suitable bone marrow donor is available.
- Patient does not have aplastic anemia, severe combined immunodeficiency (SCID), Fanconi anemia, or dyskeratosis congenita.
- Patient does not weigh more than 220 pounds (100 kg).
- Patient is not pregnant or breastfeeding, and if of childbearing age, agrees to use birth control for 12 months after the transplant.
- Patient has no serious organ problems (kidney, heart, lung, liver), uncontrolled infections, or other conditions that would make transplant unsafe.
- Patient has no known allergy to the medicines tacrolimus or mycophenolate mofetil (used to prevent graft-versus-host disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding back certain immune cells after a stem cell transplant can help prevent serious viral or fungal infections. It's for children and young adults up to age 25 who need a transplant for a blood cancer or other curable disease.
This early-stage study tests a specific chemotherapy “conditioning” regimen to prepare the body for a bone marrow transplant in children with certain non-cancer blood or immune conditions. It may help the transplant work better, but it also carries risks from the chemotherapy and transplant process.
This Phase 2 trial tests a stem cell (bone marrow) transplant approach to restore bone marrow function and immune function in people with certain inherited immune problems. If you have one of these conditions and a suitable donor, the study may offer a path to rebuild blood and immune systems.
This study tests a way to lower the chance of graft-versus-host disease (a common side effect of stem cell transplants) by removing certain immune cells from the donor's stem cells before they are given to you. It is for older patients with acute leukemia or MDS who are getting a transplant.
This trial tests a combination of four medicines (cyclophosphamide, abatacept, vedolizumab, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant for children and young adults with certain blood cancers. The goal is to see if this approach reduces the risk of GVHD, a serious complication where donor cells attack the body.
This trial provides a special type of stem cell transplant for people under 22 years old who don't have a fully matched sibling donor. It uses a method to remove certain cells from the donor's stem cells to reduce the risk of graft-versus-host disease, where the donor cells attack the patient's body.
Hear when a new Bone Marrow Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.